Latest Puramed Bioscience (PMBS) Headlines Energy

New Post Public Reply Private Reply Replies (1) Message Board

Mar 11, 2014 at 12:36 AM

Latest Puramed Bioscience (PMBS) Headlines

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
PR Newswire - Fri Nov 29, 8:00AM CST
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB

MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB

MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.

PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
PR Newswire - Thu May 30, 10:11AM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
PR Newswire - Thu May 23, 1:10PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.

LipiGesic® M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications
PR Newswire - Tue May 21, 1:33PM CDT
PuraMed BioScience®, Inc., (OTCBB

MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic® M, has "robust efficacy".

PuraMed BioScience®, Inc., Launches Its Business-to-Business Migraine First Aid Kit(TM) to Promote Workplace Health and Wellness
PR Newswire - Wed May 15, 3:01PM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit(TM). The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms.

PuraMed BioScience reaches agreement with Biokemical for distribution of LipiGesic M in Colombia, South America
M2 - Tue May 14, 8:34AM CDT
Healthcare products company PuraMed BioScience Inc (PMBS:OTCBB) reported on Monday that it has received its first International order for its non-drowsy, clinically tested, over-the-counter migraine relief product, LipiGesic M.

PuraMed BioScience® Expands International Distribution with Order from Colombia, South America
PR Newswire - Mon May 13, 10:13AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces the receipt of its first International order for LipiGesic® M its non-drowsy, clinically tested, over-the-counter migraine relief product.

Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation
PR Newswire - Wed Apr 24, 8:49AM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic® M. Report Highlights

PuraMed BioScience to Expand Marketing of Over-the-Counter Migraine Product to Additional National Retail Chains
PR Newswire - Fri Apr 12, 11:34AM CDT
Healthcare product developer PuraMed BioScience®, Inc. (PMBS: OTCBB) announced plans this week to expand the retail sales efforts of its OTC migraine product LipiGesic® M to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target, food store chains such as SuperValu, Kroger and Safeway, and additional well-known regional drugstores. PuraMed has selected its targeted retailers according to various material criteria, including cost of entry, geography, demographics and consumer preference.

PuraMed BioScience, Inc. (PMBS) Stock Research Links

PMBS Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cosign's Solution for Renters Struggling in Michigan

Breaking the Mold on Renting Approvals in Michigan Over in Ann Arbor, Michigan, the rental market ain't all sunshine and roses for folks trying to snag a place to live. The vacancies are unusually high—a whopping 8.9%—yet people are still being turned away. Why? Because rigid credit scores are tossing deserving renters aside like yesterday's news. Now, here comes...

Envision's 800V DC System Cuts the Powercake First

Envision Hits a Milestone in AI Power Dynamics You ever feel like the future is knocking on your door, but you've still got your headphones on? Well, Envision just kicked the door open with the world's first commercial deployment of an integrated 800-volt direct current (800V DC) power system in a large-scale AI data center. This technological marvel is now up and running...

LITEON's Q3 Surge: Record Profits, AI Focus Amplified

LITEON Smashes Q3 Records, Financials Speak Volumes You don't find numbers like these under every rock. LITEON Technology is rolling in it after clinching third quarter revenues of NT$57.4 billion, marking a significant 9% growth compared to the previous quarter and a whopping 28% surge year-over-year. That's the kind of financial football that gets investors holding onto...

China's Innovation Surge: Game Changer for Global Markets

The Bold Shift in China's Economic Landscape Well, here's the scoop: China isn't just the world's assembly line anymore; it's gearing up to be a top-tier innovation hub. On the surface, might seem like another geopolitical spiel, but dig a little and you'll find it's a serious shake-up for global markets. We're talking about more than just products rolling out of...

Gamehaus Expands with Anamana AI-Driven Acquisition

Gamehaus Moves Deep Into AI Waters Sailing right into a new frontier, Gamehaus is all set to splash $19.6 million for a hefty slice of Techforge, the parent of the AI-powered Anamana. Gamehaus: a game publisher taking aim at becoming an AI content giant. You might ask yourself, "Can they pull it off?" Well, that's what I'm pondering over my lukewarm coffee today....

Stellantis Harnesses AI for Customer Connection Boost

Trading Mayhem: Pre-Market Vibes Ever put your ear to the ground on the NYSE floor and felt that buzz of untamed optimism clashing with skepticism? Today it's all about connections, from the data-driven to the familial. Imagine Stellantis (NYSE: STLA) is making a play, aligning with Amperity in an ambitious attempt to make customer interactions feel more personal. Now,...

Good Springs Earns Spot on Inc.'s 2026 Founder List

There's a badge of honor in the investment world that's not about the dollars and cents pouring in—it's about having founders trust you to take care of their business babies. Good Springs Capital just snagged one by being named to Inc.'s 2026 Founder-Friendly Investors list. Now, if you're thinking this is just some fancy accolade, let's chew over the real nuggets here....

Tenax Therapeutics Faces Class Action Amid Massive Loss

Investors Eye Deadline Amidst Legal Storm Holy moly, Tenax Therapeutics is caught with their pants down—and we're not talking loose change. Any sorry soul who bought into Tenax's promises about their TNX-103 drug is now staring down a high-stakes class action lawsuit. If you were holding on to those dreams turned nightmares between November 13, 2023, and August 7, 2026,...

Lectric Rolls Out Limited-Edition XP4 Ebike Upgrades

Pedaling into a New Era of eBikes When the top contender in the American eBike world rolls out something new, you'd better believe it's worth a look. Lectric eBikes has just unwrapped three limited-edition versions of their beloved XP4, revealing a fresh take on a ride already admired by thousands. Let's dig into this new release. What's New with the XP4 This ain't just a...

E-commerce Player Temu Protects GIs in New Partnership

Temu Takes Action on Geographical Indications You ever get the feeling some companies actually give a damn about what they’re selling? Well, Temu's making moves that seem to argue just that. By stepping into the fold with oriGIn, the global network protecting Geographical Indications (GIs), Temu is staking its claim on protecting authenticity in the vast e-commerce...